Used as an intermediate in the synthesis of targeted protein degraders, particularly cereblon E3 ligase modulators. It plays a key role in the development of immunomodulatory drugs for treating hematological cancers such as multiple myeloma and myelodysplastic syndromes. The compound enables the selective recruitment of target proteins for ubiquitination and subsequent degradation by the proteasome. It is also employed in the construction of PROTACs (proteolysis-targeting chimeras) due to its high binding affinity to cereblon. Its chiral purity is critical for maintaining biological activity and minimizing off-target effects in therapeutic applications.